| 摘要 |
<p>The invention features the use of whole blood samples or samples comprising peripheral blood mononuclear cells (PBMCs) for diagnosing or evaluating the progression or treatment of leukemia. Genes that are differentially expressed in un-fractionated PBMCs of leukemia patients, as compared to in disease-free humans or in patients who have a differential type of leukemia, can be identified according to the invention. These genes are leukemia disease genes and can be used to detect the presence or progression of leukemia in a subj ect of interest. Leukemias that are amenable to the present invention include, but are not limited to, acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Non- limiting examples of AML or MDS disease genes are provided in Tables 2, 4 and 6.</p> |
